Study Finds 0.92% PSC Prevalence in Asian IBD Patients

A multicenter study of 51,314 inflammatory bowel disease patients across six Asian countries reports primary sclerosing cholangitis rates and outcomes.

Updated on Nov. 12, 2026 in Cancer

Study Finds 0.92% PSC Prevalence in Asian IBD Patients

A multicenter retrospective study of 51,314 inflammatory bowel disease patients from 25 hospitals in six Asian countries found primary sclerosing cholangitis (PSC) prevalence of 0.92%. The research also tracked how PSC presentation and outcomes have changed across five diagnostic eras.

Why it matters

The findings add Asian-population data to a condition that has been studied mostly in Western cohorts, where PSC is more common. Evidence that PSC is being detected earlier and presenting with milder symptoms could shape how clinicians screen inflammatory bowel disease patients for liver involvement.

The study reports 0.92% PSC prevalence across 51,314 IBD patients, with 1.4% in ulcerative colitis compared with 0.13% in Crohn's disease. Among 375 PSC-IBD patients, 9.1% developed colorectal neoplasia and 7.2% developed cholangiocarcinoma, while the timing of PSC-related outcomes across the five diagnostic eras remains to be fully characterized.

The details

Researchers conducted a retrospective cohort study across 25 hospitals in six Asian countries, finding 474 patients with PSC. Patients in more recent diagnostic eras presented with fewer symptoms, lower alkaline phosphatase levels and better liver function scores, and the time to liver transplantation was significantly longer (P=0.016), which the authors link to increased use of magnetic resonance cholangiopancreatography.

Timeline

  1. Recent diagnostic eras showed earlier PSC detection, milder symptoms and longer time to liver transplantation than earlier eras.

Health Landscape

The study fits into a broader pattern in which magnetic resonance cholangiopancreatography has increasingly enabled earlier detection of primary sclerosing cholangitis in inflammatory bowel disease patients. Its Asian-cohort data add to the largely Western evidence base on how PSC presents and progresses over time.

For people living with inflammatory bowel disease, the study suggests that PSC may be detected earlier and with fewer symptoms, which could affect when liver-related screening is discussed with a gastroenterologist. The reported 9.1% colorectal neoplasia and 7.2% cholangiocarcinoma rates underline why ongoing monitoring matters for this patient group.

The takeaway

Patients with inflammatory bowel disease should ask their clinicians whether liver screening for PSC is appropriate, since the study links earlier detection to milder presentation and better liver function. Routine monitoring remains important because cancer and transplant-related outcomes are documented in this population.

Further reading

Explore more on Cancer to see how related gastrointestinal and bile duct conditions are tracked alongside other diseases.

Source note: This article includes information reported by Derm Immuno Today.